Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into ...

The startup has opened labs in New York and Taipei, but it’s competing in AI drug development with larger biotech firms and newcomers such as Isomorphic Labs, the spinoff from Google DeepMind.

It follows shortly after another Alphabet start-up, Isomorphic Labs, announced its first pharma partnerships with Eli Lilly and Novartis, collectively worth almost $3 billion and focused on the ...

Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company's newly established ...

Isomorphic Labs, together with Google DeepMind, developed and released AlphaFold 3 in May 2024, a revolutionary AI model that can predict the structure and interactions of all of life's molecules ...

What was it like to track the rising danger of this asteroid, and to ultimately determine that it’d miss us? This is the ...